Royalty Pharma has seen a significant level of activity in the stock market highlighted by various institutional buying and selling. Major purchases were made by Aberdeen Group plc, Invesco Ltd., Kovitz Investment Group Partners LLC, OneAscent Investment Solutions LLC, Cetera Investment Advisers, Cookson Peirce & Co. Inc., Mitsubishi UFJ Asset Management Co. Ltd., and Jupiter Asset Management Ltd. Simultaneously, there have been some strategic selloffs by Aberdeen Group, State of New Jersey Common Pension, Fox Run Management LLC, Virtu Financial LLC, Deutsche Bank AG, and Forsta AP Fonden. The net impact of these actions reflects the strong outlook of the company's financials. There have also been discussions about strategies to average down on Royalty Pharma’s stock using swing trade techniques. Rapid uptrends in prices have been reported, with the stock hitting multiple 52-week highs. Wall Street Zen has endorsed a 'buy' position on the stock while BofA Securities has boosted its price target to $48. Despite a miss in Q1 earnings, there are expectations for a strong recovery due to the company’s robust growth trajectory. Also worth noting is the board exiti of Royalty Pharma's Henry Fernandez.
Royalty Pharma Stocks News Analytics from Wed, 07 May 2025 07:00:00 GMT to Sat, 23 Aug 2025 21:42:13 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor 4
